Tuesday, 11 September 2018

07:15 - 08:15

BRM-02 | Bayer: TRK fusion cancer testing and its importance in precision oncology

Barria
Chair: Frédérique Penault-Llorca, France

001 07:15 – 07:20
Welcome and introduction
Frédérique Penault-Llorca, France

002 07:20 – 07:40
The role of TRK fusions in oncogenesis
Frédérique Penault-Llorca, France

003 07:40 – 08:00
TRK fusion cancer testing
Albrecht Stenzinger, Germany

004 08:00 – 08:15
Q & A
All faculty

BRM-03 | Biocartis: The launch of the fully automated Idylla TM MSI Test: A new era in molecular MSI Testing

Room A2
Chair: Caroline Jans, Belgium

001
A new era in MSI testing –Discovery, benefits and clinical performance of Idylla™MSI
Bram De Craene, Belgium

002
Clinical evidence on Idylla™MSI in colorectal cancer; a multi-center evaluation
Elena Guerini Rocco, Italy

003
The Idylla™MSI: A laboratory user perspective
Sofie Metsu, Belgium


13:00 - 14:30

LS-09 | BMS: Precision Medicine Starts with Pathology: Immuno-Oncology Biomarkers and Your Practice

Room A1
Chair: Reinhard Büttner, Germany

001 13:00 – 13:05
Welcome and introductions
Reinhard Büttner, Germany

002 13:05 – 13:10
The need for precision medicine through biomarkers in Immuno-Oncology (I-O)
Nicola Normanno, Italy

003 13:10 – 13:25
Programmed death ligand 1 (PD-L1): The first wave in I-O biomarkers
Reinhard Büttner, Germany

004 13:25 – 13:45
Exploring the next wave in I-O biomarkers: Tumour mutational burden (TMB)
Nicola Normanno, Italy

005 13:45 – 14:05
Testing for TMB and other genomic biomarkers
Frédérique Penault-Llorca, France

006 14:05 – 14:15
What is on the horizon?
Reinhard Büttner, Germany

007 14:15 – 14:25
Q & A session
All faculty

008 14:25 – 14:30
Closing remarks
Reinhard Büttner, Germany

LS-10 | Roche: Advancements in Cancer Diagnostics and Decision Support Technology - from Glass Slide to Tumor Board

Room A3
Chair: Julien Adam, France

001 13:00 – 13:05
Welcome and introduction
Julien Adam, France

002 13:05 – 13:40
PD-L1 testing and digital pathology tools – Two worlds brought together
Julien Adam, France

003 13:40 – 14:15
The Digital Tumour Board as a tool to advance clinical decision support
Matthew Prime, United Kingdom

004 14:15 – 14:30
Discussion
Julien Adam, France

LS-11 | Menarini: Liquid biopsy: clinical applications of CTSs in cancer patients

Room E
Chair: Cecilia Simonelli, Italy

001
CTC enumeration and molecular characterisation: Potential and clinical applications
Evi Lianidou, Greece

002
Clinical impact of CTC count in early and late breast cancer
Francois Clement Bidard, France

003
Genomic profiling of circulating tumour cells
Nicholas Stoecklein, Germany